Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Regeneus Ltd. ( (AU:CMB) ) has provided an update.
Cambium Bio Limited has disclosed a change in director Yu-Hung Sebastian Tseng’s interests following a recent share placement. Tseng, who holds shares directly and through Zheng Yang Biomedical Technology Limited, increased his indirect holding as part of the company’s capital-raising activities.
Under the transaction, Zheng Yang Biomedical Technology Limited acquired 4,363,637 ordinary shares at $0.55 each, lifting its stake to 10,862,136 shares, while Tseng’s direct holding remained unchanged. The acquisition, issued via a placement announced in January 2026, consolidates Tseng’s exposure to Cambium Bio and signals strengthened insider alignment with the company’s future performance.
The most recent analyst rating on (AU:CMB) stock is a Hold with a A$0.46 price target. To see the full list of analyst forecasts on Regeneus Ltd. stock, see the AU:CMB Stock Forecast page.
More about Regeneus Ltd.
Cambium Bio Limited, formerly associated with Regeneus Ltd., operates in the biotechnology and biomedical sector. The company’s activities involve advanced biomedical technologies, with equity holdings including stakes held through Zheng Yang Biomedical Technology Limited, reflecting a capital structure typical of clinical- and research-focused biotechs.
Average Trading Volume: 11,883
Technical Sentiment Signal: Sell
Current Market Cap: A$13.12M
Learn more about CMB stock on TipRanks’ Stock Analysis page.